The life-saving efficacy of plasma therapy is known for decades but our understanding of iTTP has only been revolutionized in early 2000, when severe acquired ADAMTS13 deficiency was recognized as the key pathogenic event and led to dissecting the TTP/HUS spectrum [14–16]. Here, ADAMTS13 is linked to thrombotic thrombocytopenic purpura.